Blue Laser Therapy for Enlarged Prostate: How It Works, Benefits, and Recovery Explained

KUALA LUMPUR, PANTAI HOSPITAL PENANG, 30 SEPTEMBER 2026 —

Kuala Lumpur, Malaysia — Dr. William Ong Lay Keat performed Malaysia’s first blue laser prostate vaporisation procedure at Pantai Hospital Penang on March 25, 2026, marking a significant advancement in the local treatment of benign prostatic hyperplasia (BPH).

Benign prostatic hyperplasia is a common, non-cancerous condition characterised by the enlargement of the prostate gland, which often affects urinary flow in older men. Symptoms typically include weak urine flow, frequent urination, and the sensation of incomplete bladder emptying. As the prevalence of BPH increases with an ageing population, there is a growing demand for safer, more precise, and minimally invasive treatment options.

Traditional procedures, such as transurethral resection of the prostate (TURP), have long been the standard of care, but they are associated with specific complications that can impact patient quality of life.

The blue laser therapy utilises a 450 nm laser to vaporise and remove enlarged prostate tissue. First introduced into clinical practice in 2022, this technology offers high precision, improved haemostasis, and targeted tissue removal. In practical terms, this allows surgeons to remove obstructing prostate tissue accurately while minimising damage to nearby tissues. The procedure represents a shift towards minimally invasive prostate care with better preservation of surrounding structures, including those related to sexual function.

By delivering energy with high specificity, the technology aims to preserve important anatomical structures involved in normal ejaculatory pathways and erectile function.

In the Malaysian context, the adoption of this technology addresses specific clinical challenges faced by the local patient demographic. Many patients with prostate enlargement in Malaysia are elderly and may have coexisting medical conditions such as hypertension, diabetes, or cardiovascular disease. These comorbidities can increase surgical risk and make treatment decisions more complex for urologists.

Blue laser therapy offers distinct advantages in this context, including shorter operative times, reduced bleeding, and a lower risk of complications. Consequently, it may be a suitable option for patients who are on antiplatelet or anticoagulant medications, a group that often faces higher risks with conventional surgical approaches.

The introduction of this procedure follows regulatory clearance and clinical evaluation, ensuring that the technology meets local safety and efficacy standards. Dr. Ong, who is among the early adopters of this technique, observed and evaluated its clinical application in high-volume international centres before bringing the capability to Malaysia. The successful execution of the first local case on March 25, 2026, confirms the feasibility of the procedure in a Malaysian hospital setting.

Pantai Hospital Penang is now equipped with the advanced blue laser technology, enabling precise and minimally invasive treatment for BPH patients.

Emerging clinical data continues to support the effectiveness of blue laser therapy, with recent studies published in 2025 reporting improvements in urinary symptoms within three months after treatment. These studies also noted a reduced risk of complications compared to traditional methods. Comparative analyses suggest that blue laser vaporisation may offer advantages over conventional techniques in terms of operative efficiency, bleeding control, and recovery speed.

While longer-term data will further consolidate these findings, the current evidence is described as highly encouraging, positioning blue laser therapy as a strong contender among modern surgical options for prostate enlargement.

One of the key concerns for many patients undergoing prostate surgery is the impact on sexual function. Conventional procedures such as TURP are effective but may be associated with complications such as retrograde ejaculation and, in some cases, erectile dysfunction. In contrast, blue laser technology is designed to minimise damage to surrounding tissues. Its precise energy delivery allows for targeted tissue removal while preserving the anatomical structures involved in sexual function.

This approach supports better preservation of normal ejaculatory pathways and erectile function, contributing to improved postoperative quality of life and higher patient satisfaction.

With faster recovery and shorter hospital stays, this treatment is particularly well suited for patients who are considered higher-risk surgical candidates. The ability to manage BPH with reduced bleeding and shorter operative times aligns with the needs of an ageing population with complex medical histories. Pantai Hospital Penang provides personalised care for prostate conditions, including these advanced minimally invasive options.

Patients experiencing symptoms that may suggest an enlarged prostate are advised to speak to a urologist to better understand their condition and explore suitable treatment options, ensuring that care is tailored to individual health profiles and surgical risks.

Related: Dr. William Ong Lay Keat